On Jan. 17, 2020, the Non-profit drug developer TB Alliance granted Shenyang Hongqi Pharmaceuticals , a subsidiary of Shanghai Fosun Pharmaceutical a license to market the anti-TB medicine pretomanid as part of the three-drug ﾓBPaLﾔ regimen.

Hongqi Pharma agreed to commercialize the anti-tuberculosis medicine in the Peopleﾒs Republic of China.